AI주식인사이트AI Stock Insight
B

코미팜

041960KOSDAQ

57.0 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum16.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 19.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Komipharm is a company established in 1972 specializing in the production and sale of animal vaccines and pharmaceuticals, with key products including ASF vaccines and Pro-vacTM PED-Fc. It is actively expanding globally through the development of cancer treatment drug PAX-1. In 2024, sales increased by 38% year-on-year to 58.8 billion won, with operating profit from animal pharmaceuticals reaching 89.77 billion won.

Number of Employees

172people

Average Salary

47.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
10.17Industry Average 1.200.0Point

8.5x industry avg (risky)

ROE
-11.67Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
12.64Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.5% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲65.2% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 0.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position8.0Point

Near 52w high (91%, uptrend)

Current 9,920Won52-week high 10,31052-week low 5,890
1-month return6.0Point

1m +19.23% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-13